Strong HIFU revenue and system sales growth are overshadowed by the $40M dilutive offering announced alongside this earnings release. The net loss excluding the warrant charge (~$8.9M) is still meaningfully worse than consensus EPS of -$0.20. With shareholders' equity now negative and a dilutive capital raise underway, near-term stock pressure likely outweighs the positive commercial momentum. Monitor post-offering share structure and cash runway.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 14 $4.76entry
- T+1 · 3mo ago −8.40%α −7.93% · $4.36
- T+5 · 3mo ago −13.24%α −11.87% · $4.13
- T+20 · 2mo ago −13.66%α −11.66% · $4.11
- T+60 · 8d ago −26.05%α −23.00% · $3.52
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
FocalTherics (FOCL) reported strong Q2 2026 HIFU continuing operations revenue of $13.2M (+39% YoY), with 13 Focal One system sales (+44% YoY) and 47% US procedure growth. However, the net loss widened to $14.4M ($0.38 loss per share) from $6.4M ($0.17 loss) due to a $5.5M EIB warrant valuation charge, and the company announced a $40M dilutive public offering. Management reiterated full-year 2026 revenue guidance of $50-54M (34-45% YoY growth).
Key Financial Metrics
Key Facts
- HIFU continuing operations revenue rose 39% YoY to $13.2M (Q2 2026 vs Q2 2025: $9.5M); consensus was $15.1M.
- 13 Focal One capital system sales in Q2 2026 vs 9 in prior year period, including 2 lease conversions (+44% YoY).
- Gross margin improved to 55.6% from 51.1% YoY.
- Net loss from continuing operations was $14.4M ($0.38/share) vs $6.4M ($0.17/share) in Q2 2025, the increase was primarily due to a $5.5M loss from change in fair value of warrant liability.
- Adjusted net loss from continuing operations (excluding the $5.5M warrant impact) was approximately $8.9M ($0.24/share), which is near consensus EPS of -$0.20.
- Management reiterated 2026 full-year guidance for continuing operations: total revenue of $50.0-54.0M (34-45% YoY growth).
- Announced an underwritten public offering for $40M of gross proceeds, expected to close August 14, 2026.
- Completed corporate name change to FocalTherics and reclassified ESWL/Distribution segments as discontinued operations.
- Cash and cash equivalents of $21.5M as of June 30, 2026.
- Shareholders' equity was negative ($3.2M) as of June 30, 2026 (vs positive $19.4M at Dec 31, 2025), driven by a large warrant liability.
Financial Impact
Revenue up 39% YoY to $13.2M; net loss widened to $14.4M largely due to $5.5M non-cash warrant revaluation. $40M dilutive offering to close Aug 14.
Risk Factors
- $40M dilutive public offering will increase share count significantly, potentially diluting existing shareholders by >20% given current market cap of ~$178M.
- Negative shareholders' equity of -$3.2M and large warrant liability ($6.9M related to Tranche A and B borrowings) indicate balance sheet strain.
- Operating cash flow remained negative at -$6.7M for H1 2026, suggesting ongoing reliance on external capital.
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-005498 |
| Document: f8k_081326.htm | 0001171843-26-005498 |
| Document: 0001171843-26-005498-index-headers.html | 0001171843-26-005498 |
| Document: 0001171843-26-005498-index.html | 0001171843-26-005498 |
| Document: 0001171843-26-005498.txt | 0001171843-26-005498 |
| 8-K Data (Synthetic) | 0001171843-26-005498 |
Track record
9 reports on FOCL
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +26.05% at T+60 after the Aug 14, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $3.32 Now $3.17 −4.52% settles Feb 4
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $4.15 Now $3.17 −23.61% settles Jan 21
- Oct 19, 202628d ago SC 13G Neutral 3/10 Entry $4.07 Now $3.17 −22.11% settles Jan 14
- Aug 19, 202612w ago 8-K Bearish 6/10 Entry $4.36 to $3.41 Now $3.17 +27.29% ▲ +21.79% +20.24% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $4.76 to $3.52 Now $3.17 +33.40% ▲ +26.05% +23.00% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 Viewing Entry $4.76 to $3.52 Now $3.17 −33.40% ▼ −26.05% −23.00% vs SPY
- Aug 11, 202613w ago Press Release Mixed 6/10 Entry $4.75 to $4.25 Now $3.17 −33.26% ▼ −10.53% −5.41% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $4.75 to $4.25 Now $3.17 −33.26% ▼ −10.53% −5.41% vs SPY
- Jul 30, 202615w ago Press Release Neutral 1/10 Entry $6.12 to $4.23 Now $3.17 −48.20% ▼ −30.88% −33.34% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers